RHUMBLINE ADVISERS

Position in CRDF — Cardiff Oncology, Inc.

CIK 1115418 BOSTON, MA

Position in CRDF

as of Mar 31, 2026 · filed May 12, 2026 Compact

Position Value

$119,711

-$100,562 QoQ

Shares Held

73,896

-5.7% QoQ

Ownership

0.108%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2021

12 quarters on record

Voting authority Sole 18% Shared 0% None 82%

Healthcare · as of Mar 31, 2026

RHUMBLINE ADVISERS holds $1,238,289,073 across 287 Biotechnology names. CRDF ranks #219 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	423,140	$188,948,935
2	REGN	Regeneron Pharmaceuticals, Inc.	157,781	$121,907,911
3	INCY	Incyte Corp	693,665	$65,287,749
4	ALNY	Alnylam Pharmaceuticals, Inc.	195,277	$64,611,300
5	INSM	INSMED Inc	272,615	$44,578,004
6	JAZZ	Jazz Pharmaceuticals plc	164,542	$31,106,665
7	EXEL	Exelixis, Inc.	723,931	$31,049,400
8	ROIV	Roivant Sciences Ltd.	1,113,266	$30,837,468

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$119,711	73,896	-5.7%	Shares	Sole	2026-05-12
2025-12-31	$220,273	78,389	-10.2%	Shares	Sole	2026-02-13
2025-09-30	$179,747	87,256	+2.9%	Shares	Sole	2025-11-06
2025-06-30	$266,990	84,759	+34.2%	Shares	Sole	2025-08-12
2025-03-31	$198,265	63,142	+18.8%	Shares	Sole	2025-05-29
2024-12-31	$230,766	53,172	+24.0%	Shares	Sole	2025-05-29
2024-09-30	$114,494	42,882	-6.8%	Shares	Sole	2024-11-12
2024-06-30	$102,104	45,993	-0.6%	Shares	Sole	2024-08-01
2022-03-31	$114,799	46,290	-0.6%	Shares	Sole	2022-05-12
2021-12-31	$279,969	46,584	-2.2%	Shares	Sole	2022-02-10
2021-09-30	$317,349	47,650	+4.3%	Shares	Sole	2021-11-12
2021-06-30	$303,838	45,690	—	Shares	Sole	2021-08-05
No filing history on record for this holder in this stock.